Clinical Policy: Nerve Blocks and Neurolysis for Pain Management Form

Chat with GenHealth to automate any policy or prior auth task.


Clinical Policy: Nerve Blocks and Neurolysis for Pain Management

Indications

(10001) Does the patient have unilateral pain located in the distribution of the greater, lesser and/or third occipital nerves? 
(10002) Does the patient have bilateral pain located in the distribution of the greater, lesser and/or third occipital nerves? 
(20001) Does the pain recur in paroxysmal attacks lasting from a few seconds to minutes? 
(20002) Is the pain severe in intensity? 
(20003) Is the pain shooting, stabbing, or sharp in quality? 

YesNoN/A
YesNoN/A
YesNoN/A

Sign up to see the rest of the questions

Unlock the remaining questions and the full coverage workflow.

Sign up for free
Effective Date

NA

Last Reviewed

NA

Original Document

  Reference



Clinical Policy: Nerve Blocks and Neurolysis for Pain Management Reference Number: OH.CP.MP.170                                               Coding Implications Date of Last Revision: 10/25                                               Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Policy Statement In compliance with Ohio Medicaid, Buckeye Health Plan must ensure coverage of medically necessary procedures. The plan covers all the services in the amount, duration, and scope that is no less than that covered by FFS Ohio Medicaid and in accordance with 42 CFR 438.210, with limitations, exclusions, and clarifications provided in the Ohio Medicaid Managed Care Provider Agreement and the Ohio Administrative Code. Buckeye Health Plan will not impose hard limits or restrictions on coverage of medically necessary services. Prior to making determinations regarding coverage of services and procedures, Buckeye Health Plan will conduct a medical necessity review for all requests to include non-covered services and any request for services over an established benefit(s).

Description Nerve blocks are the temporary interruption of conduction of impulses in peripheral nerves or nerve trunks created by the injection of local anesthetic solutions. They can be used to identify the source of pain or to treat pain.

Note:

  •   For sacroiliac nerve block and radiofrequency neurotomy, please refer to CP.MP.166 Sacroiliac Joint Interventions.
  •   For facet joint injections and radiofrequency neurotomy, please refer to CP.MP.171 Facet Joint Interventions.
  •   For criteria applicable to Medicare plans for peripheral nerve blocks and ablation of peripheral nerves, please refer to MC.CP.MP.170 Peripheral Nerve Blocks and Ablation of Peripheral Nerves for Pain Management.

Policy/Criteria It is the policy of health plans affiliated with Centene Corporation® that invasive pain management procedures performed by a physician are medically necessary when the relevant criteria are met and the patient receives only one procedure per visit, with or without radiographic guidance.

Table of Contents I.   Occipital Nerve Block........................................................................................................2 II.  Sympathetic Nerve Blocks..................................................................................................2 III. Celiac Plexus Nerve Block/Neurolysis.................................................................................3 IV. Intercostal Nerve Block/Neurolysis.....................................................................................3 V.  Genicular Nerve Blocks and Genicular Nerve Radiofrequency Neurotomy ...............................4 VI. Peripheral nerve blocks........................................................................................................4 VII. Intraosseous radiofrequency nerve ablation of basivertebral nerve...........................................5

CLINICAL POLICY Nerve Blocks and Neurolysis for Pain Management

I. Occipital Nerve Block A. An initial injection of a local anesthetic for the diagnosis of suspected occipital neuralgia is medically necessary when all of the following are met:

  1. Patient has unilateral or bilateral pain located in the distribution of the greater, lesser and/or third occipital nerves;
  2. Pain has two of the following three characteristics: a. Recurring in paroxysmal attacks lasting from a few seconds to minutes; b. Severe intensity; c. Shooting, stabbing, or sharp in quality;
  3. Pain is associated with dysesthesia and/or allodynia apparent during innocuous stimulation of the scalp and/or hair, and at least one of the following: a. Tenderness over the affected nerve branches; b. Trigger point at the emergence of the greater occipital nerve or in the distribution of C2.

B. Therapeutic occipital nerve blocks are medically necessary when all of the following are met:

  1. There was temporary relief from the initial/previous injection;
  2. The member/enrollee has failed 3 months of conservative treatment including all of the following: a. Heat, rest and/or physical therapy, including massage; b. NSAIDS, unless contraindicated or not tolerated; c. Oral anticonvulsant medications (e.g., carbamazepine, gabapentin, pregabalin) or tricyclic antidepressants; d. Activity modification to address triggers;
  3. No more than 4 injections are to be given within 12 months (includes diagnostic injection).

C. Occipital nerve block for the diagnosis or treatment of other types of headaches, including migraine and cervicogenic headaches, is considered not medically necessary as effectiveness has not been established.

Note: Please refer to CP.PHAR.232 OnabotulinumtoxinA (Botox) for requests for Botox injections for migraines

II. Sympathetic Nerve Blocks have limited evidence to prove effectiveness of treatment and consideration will be made on a case by case basis. The criteria below provide a basis for documenting patient-specific clinical information to help guide clinical decision making. i. A first or second sympathetic nerve block:

  1. Diagnosis of complex regional pain syndrome (CRPS) (also called reflex sympathetic dystrophy) and all of the following: a. Pain is being managed by a pain management specialist with experience treating CRPS; b. The member/enrollee is in an active rehabilitation regimen; c. Failed ≥ 3 weeks of conservative therapies such as activity modification, exercises, topical application of lidocaine or topical capsaicin cream, and oral medical management such as nonsteroidal anti-inflammatories, antidepressants, anticonvulsants and glucocorticoids; d. Two or more of the following findings of the involved digit/extremity: i. Hyperalgesia or allodynia (pain sensation in response to a typically non- painful stimulus); ii. Evidence of edema and/or sweating changes and/or sweating asymmetry; iii. Evidence of temperature asymmetry (>1°C) and/or skin color changes and/or asymmetry; iv. Evidence of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin).

ii. Additional sympathetic nerve blocks for CRPS may be considered medically necessary when all of the following are met:

  1. Nerve blocks are given at least a week apart;
  2. There was an immediate positive response to the first or second nerve block (e.g., improved temperature and decreased pain).

iii. Additional sympathetic nerve blocks without documented benefit from the first or second are not medically necessary.

iv. Sympathetic nerve blocks for any other indication, including ischemic limb pain, are not medically necessary as there is a lack of evidence to support effectiveness.

III.Celiac Plexus Nerve Block/Neurolysis A. Celiac plexus nerve block/neurolysis is medically necessary for either of the following indications:

  1. Chronic neuralgic pain secondary to pancreatic cancer, all of the following: a. Diagnosis of pancreatic cancer with severe visceral abdominal/back pain; b. Strong analgesics such as opioids are no longer effective or their side effects decrease quality of life; c. No malignancy in an area of somatic innervation such as the peritoneum or diaphragm.
  2. Refractory pain due to to chronic pancreatitis with non-dilated pancreatic duct.

B. A repeat celiac plexus nerve block for refractory pain from chronic pancreatitis with non- dilated pancreatic duct is medically necessary when both of the following are met:

  1. At least three months have passed since previous injection;
  2. There was a clinical benefit from the initial celiac block.

C. Repeat celiac plexus nerve blocks or neurolysis, for any indication other than those noted above, are not medically necessary as there is a lack of evidence to support effectiveness.

IV. Intercostal Nerve Block/Neurolysis A. Intercostal nerve block/neurolysis is medically necessary for chronic neuralgic pain secondary to an injured intercostal nerve as a result of a rib fracture, a thoracotomy incision or chronic pain due to post herpetic neuralgia, or other neuropathic process when all of the following are met:

  1. Suspected organic problem;
  2. Non-responsiveness to conservative modalities of treatment;
  3. Pain and disability of moderate to severe degree;
  4. No evidence of contraindications such as infection or pain of predominately psychogenic origin.

V. Genicular Nerve Blocks, Neurolysis and Genicular Nerve Radiofrequency Neurotomy There is insufficient evidence to determine safety and effectiveness of genicular nerve blocks, neurolysis and radiofrequency neurotomy of the articular nerve.

VI.Peripheral/Ganglion Nerve Blocks Note: If administered as part of a surgery or other procedure, coding for peripheral/ganglion nerve blocks should follow proper coding practices and would not be subject to prior authorization or payment separately from the procedure.

A. Peripheral nerve blocks for diagnosis and treatment of malignant pain are considered medically necessary as part of a comprehensive pain management program.

B. Peripheral nerve blocks for diagnosis or treatment of post-herniorrhaphy pain are considered medically necessary when all of the following criteria are met:

  1. A first diagnostic peripheral nerve block when all of the following are met: a. Diagnosis of post-herniorrhaphy neuralgia; b. Groin pain has persisted for three months after surgical hernia repair; c. Less invasive pain management methods such as NSAIDs and/or opiates have not relieved the pain; d. Imaging studies have ruled out non-neuropathic causes of pain; e. Documentation indicates that pain is not attributable to any other cause;
  2. Therapeutic peripheral nerve block(s) for treatment of post-herniorrhaphy pain when all of the following are met: a. There was temporary relief from the initial/previous injection; b. Injections are given at least a week apart.

C. Peripheral nerve blocks for prevention or treatment of headaches, including, but not limited to migraine headaches, treatment-refractory migraines in pregnancy, and short- lasting unilateral neuralgiform headaches, are considered not medically necessary as effectiveness has not been established.

D. There is insufficient evidence in the published peer-reviewed literature to support the use of peripheral nerve blocks for the treatment of trigeminal neuralgia.

E. There is insufficient evidence in the published peer-reviewed literature to support the use of peripheral/ganglion nerve blocks or neurolysis for any condition not indicated elsewhere in this policy, including chronic pain. There is ongoing research but insufficient evidence to establish efficacy.

VII.Intraosseous Radiofrequency Nerve Ablation of the Basivertebral Nerve

There is insufficient evidence to determine the safety and effectiveness of intraosseous radiofrequency nerve ablation of the basivertebral nerve (e.g. Intracept® Intraosseous Nerve Ablation System.) for the treatment of chronic low back pain

Background Local Injections for Cervicogenic Headache and Occipital Neuralgia Greater occipital nerve blocks have been advocated as a diagnostic test for cervicogenic headache and occipital neuralgia. The effectiveness of greater occipital nerve block in patients with primary headache syndromes is controversial.²⁵ The International Headache Society (IHS) defines occipital neuralgia as unilateral or bilateral paroxysmal, shooting or stabbing pain in the posterior part of the scalp, in the distribution of the greater, lesser or third occipital nerves, sometimes accompanied by diminished sensation or dysesthesia in the affected area and commonly associated with tenderness over the involved nerve(s).¹ The IHS includes relief of pain following a local anesthetic of the affected nerve as part of their diagnostic criteria for occipital neuralgia.¹ Thus, the principal indication for occipital block is diagnosis. Another indication is the treatment of chronic occipital neuralgia, often with a series of therapeutic blocks combining local anesthetic and corticosteroid. Pain relief is typically prompt with improvement primarily noted to the sharp but not the dull component of the occipital neuralgia pain.²⁴ The pain relief may last several weeks or even months.¹ At that time the injection may be repeated.¹⁹,²⁵ The Veterans Affairs/Department of Defense (VA/DoD) also suggest greater occipital nerve block for the acute treatment of migraine in the VA/DoD Clinical Practice Guideline for the Primary Care Management of Headache.⁵⁸

Sympathetic Nerve Blocks Sympathetic nerves may be injected for several reasons:

  •   Diagnostic - to determine the source of pain, e.g., to identify or pinpoint a nerve that acts as a pathway for pain; to determine the type of nerve that conducts the pain; to distinguish between pain that is central (within the spinal cord) or peripheral (outside the spinal cord) in origin; or to determine whether a neurolytic block or surgical lysis of the nerve should be performed;
  •   Therapeutic - to treat painful conditions that respond to nerve blocks (e.g., celiac block for pain of pancreatic cancer); and
  •   Prognostic - to predict the outcome of long-lasting interventions (e.g., lumbar sympathectomy).

The response to sympathetic blockade is the best diagnostic test for CRPS (complex regional pain syndrome). If the patient has had a technically successful sympathetic block and does not obtain significant relief, then the patient probably does not have CRPS. Over two thirds of patients will obtain significant relief with minimal effect on motor and sensory function because the sympathetic fibers are the least myelinated (as compared to motor and sensory nerve fibers) and are the first to be affected by the local anesthetic.

A 2014 case report and literature review identified only five cases, and no Level I or II evidence- based trials to support the use of sympathetic nerve block for ischemic pain.¹⁶ The authors presented two cases of patients who experienced severe pain due to ischemia despite full regional nerve blocks.¹⁶ The available literature is not sufficient to support the use of sympathetic nerve blocks for ischemic limb pain.

Celiac Plexus Nerve Block/Neurolysis for Pancreatic Cancer Although its analgesic effectiveness is similar to analgesic drugs, celiac plexus neurolysis offers pain reduction without the significant adverse effects of opiates.² A multidisciplinary, international guideline issued a strong recommendation based on moderate quality evidence for celiac plexus neurolysis as a treatment for pain associated with advanced pancreatic cancer.² Furthermore, a 2011 Cochrane review stated that celiac plexus block (neurolysis) significantly reduced opiate use and lowered pain compared to the control group.³ A meta-analysis and systematic review demonstrated pain relief up to 53% to 80% of the time for the pooled proportion of patients with pancreatic cancer treated with EUS-guided celiac plexus neurolysis.⁵³

The optimal timing of celiac plexus neurolysis for pain due to pancreatic cancer is not known.² Advocates of an earlier approach argue that pain is more effectively addressed by neurolysis when treated earlier, and opiate-related side effects may also be reduced compared to later treatment. However, the effects of celiac plexus neurolysis diminish over time, which would leave a patient with fewer options as the cancer progresses and pain becomes more severe. Repeat celiac plexus neurolysis for pain due to pancreatic cancer is effective only about 30% of the time and is not recommended.²,¹⁷

Celiac Plexus Nerve Block/Neurolysis for Chronic Pancreatitis Celiac plexus blockade is an option for pain relief in patients with refractory pain due to chronic pancreatitis and a non-dilated pancreatic duct. Advantages of celiac plexus blockade include that a single treatment can potentially provide pain reduction or relief, may reduce, or eliminate the need for oral analgesia, and can be performed quickly and repeated as needed. However, it is unclear which patients will derive the most benefit and the pain relief is transient, lasting for three to six months.²⁴

The American College of Gastroenterology suggests considering celiac plexus block for treatment of pain in chronic pancreatitis (conditional recommendation, very low quality of evidence) noting that celiac plexus blockade represents a relatively low-risk, opioid-free method to reduce refractory pain in certain patients with chronic pancreatitis.⁴¹

Intercostal Nerve Blocks Intermittent intercostal nerve blocks can be used to control pain in the chest and upper abdomen, such as pain associated with rib fractures or chronic pain due to post herpetic neuralgia. Intercostal nerve blocks can be performed using anatomic landmarks or with ultrasound guidance, which can be used to minimize the chance of intravascular injection and pneumothorax and to increase reliable dermatomal coverage.⁴,⁸

For isolated injuries, such as single rib fracture, nonsteroidal anti-inflammatory drugs with or without opioids would be the initial treatment. For more severe injuries, particularly if ventilation is compromised, intercostal nerve blocks may be needed. For patients with multiple rib fractures, there is a need to perform the procedure at multiple intercostal levels. Repeated blockade may be needed for prolonged relief upon return of pain and/or deterioration in functional status. For repeat blocks or other interventions, patient must have been responsive to prior interventions with improvement in physical and functional status.⁵,⁸

Regional anesthesia plays an important role in thoracic surgery, particularly with regard to post- operative pain control. The first choice of regional anesthesia for thoracic surgery is epidural analgesia or thoracic paravertebral block. In general, the analgesic efficiencies of both these types of anesthesia are equivalent; however, thoracic paravertebral block has some advantages over epidural analgesia, including fewer complications. When these two blocks are contraindicated, intercostal nerve block or interpleural block should be considered.⁶,⁷

Genicular Nerve Blocks and Radiofrequency Neurotomy The genicular nerve is a sensory nerve that surrounds the knee and provides innervation for the joint. Genicular nerve blocks, neurolysis and radiofrequency neurotomy are emerging interventions for knee pain. The limited evidence regarding genicular nerve blocks for determining appropriateness of treatment with genicular radiofrequency ablation has reached conflicting results.⁹,¹⁰,⁴¹ A few recent studies suggest that genicular radiofrequency neurotomy may be effective for relief of pain, but further research is needed to establish safety and efficacy. ¹¹,¹²,¹³,¹⁴,¹⁵

Peripheral/Ganglion Nerve Blocks. Peripheral nerve blocks (PNB) are widely used for surgical anesthesia as well as for both postoperative and nonsurgical analgesia. Indications for PNBs are diverse and vary widely. Blocks are often used to avoid the effects of alternative anesthetics or analgesics. The most common rationale for their use is to avoid side effects and complications of general anesthesia, particularly respiratory-related effects, and to provide analgesia while minimizing opioid use.³⁷

Chronic pain can be treated with a number of pharmacologic and nonpharmacologic therapies which generally fall into six major categories: pharmacologic, physical medicine, behavioral medicine neuromodulation, interventional and surgical approaches.³³ Optimal outcomes result from multiple approaches, which typically attempt to target the presumed pain generators.³³,⁵⁰ Interventional approaches, may play a complementary role to other strategies (e.g., rehabilitation and appropriate pharmacotherapy.) The best candidates for interventional management have persistent focal pain of shorter duration, appropriate expectations, and well-managed psychosocial distress.³³

Cancer pain can be caused by complex interactions among cancer cells, the peripheral and central nervous systems, and the immune system. Peripheral pain receptors may become activated, sensitized, or injured with certain cancers. Neuropathic pain may arise from nerve tissue damage and cancer patients may experience mild to severe pain. At least 15% will experience no relief or have severe adverse effects from interventions to address their pain. Nerve blocks or other interventional procedures may be appropriate as part of a comprehensive pain management program.³⁴, ³⁵

Peripheral Nerve Blocks for Prevention or Treatment of Headaches Peripheral nerve blocks have been proposed as a treatment for migraines in pregnancy and refractory migraines. However, evidence is limited to support this indication. In a series of 13 birthing individuals with migraine refractory to medication, injection of local anesthetic into one or more peripherals nerve resulted in elimination of pain in seven individuals, pain reduction in two and no response in four. Larger studies are necessary to better define the efficacy of this approach.³¹

Peripheral Nerve Blocks for Diagnosis and Treatment of Post-Herniorrhaphy Groin Pain Persistent pain following inguinal hernia surgery is relatively common and a comprehensive pain management program is recommended. A prospective study, including elective primary open hernia repairs, found persistent pain occurred in 16.5 to 16.1 percent of patients at six months and five years.³⁶ Acute pain persisting more than eight weeks is most likely neuropathic due to primary or secondary nerve injuries. Post-herniorrhaphy neuralgia should be suspected if pain persists beyond six to eight weeks. These patients should undergo imaging to exclude nonneuropathic causes. Patients with positive response to initial nerve block can be treated every one to three weeks until pain relief is sustained. Those who have a positive response initially, but the pain returns, may require groin nerve sacrifice via percutaneous nerve ablation or surgical neurectomy.³⁶

Peripheral Nerve Blocks for Prevention or Treatment of Trigeminal Neuralgia Compression of the trigeminal nerve root is the main mechanism of trigeminal neuralgia, but brainstem lesions account for a small proportion of cases. Initial treatment of most patients with trigeminal neuralgia is pharmacologic therapy. For patients with TN refractory to medical therapy, it is reasonable to discuss options for surgical therapy (e.g., microvascular decompression, various types of rhizotomy, or gamma knife radiosurgery.) The decision to have surgery and the choice among surgical options will be influenced by individual circumstances including patient preference, adverse effect profile of the available techniques, and expertise of the local center.⁴² There is insufficient evidence in the published peer-reviewed literature to support the use of peripheral nerve blocks for the treatment of trigeminal neuralgia.⁵⁰

Intraosseous Radiofrequency Nerve Ablation of Basivertebral Nerve Basivertebral nerve radiofrequency ablation has been developed for the treatment of chronic low back pain thought to originate from the vertebral body endplates.⁴³ The Intracept Intraosseous Nerve Ablation System, Relievant Medsystems, Inc. is approved by the FDA and intended to be used in conjunction with radiofrequency generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae. Its purpose is to relieve chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI (e.g., inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change)].⁴⁹

Studies to date report relief of pain and improvement in function and quality of life after treatment, however, most are company sponsored, limited in size and are of generally poor or fair quality. A review of full-text clinical practice guidelines and position statements offers weak support for the Intracept Intraosseous Nerve Ablation for chronic low back pain of suspected vertebrogenic origin. Long-term non-industry-funded prospective trials should be pursued to confirm the results of currently published clinical studies.⁴⁴

Coding Implication Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to- date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes Description
64400 Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch (ie, ophthalmic, maxillary, mandibular)
64405 Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve
64408 Injection(s), anesthetic agent(s) and/or steroid; vagus nerve
64415 Injection(s), anesthetic agent(s) and/or steroid; brachial plexus
64417 Injection(s), anesthetic agent(s) and/or steroid; axillary nerve
64418 Injection(s), anesthetic agent(s) and/or steroid; suprascapular nerve
64420 Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, single level
64421 Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, each additional level
64425 Injection(s), anesthetic agent(s) and/or steroid; ilioinguinal, iliohypogastric nerves
64430 Injection(s), anesthetic agent(s) and/or steroid; pudendal nerve
64435 Injection(s), anesthetic agent(s) and/or steroid; paracervical (uterine) nerve
64445 Injection(s), anesthetic agent(s) and/or steroid; sciatic nerve
64447 Injection(s), anesthetic agent(s); femoral nerve
64450 Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch
64454 Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed
64505 Injection, anesthetic agent; sphenopalatine ganglion
64510 Injection, anesthetic agent; stellate ganglion (cervical sympathetic)
64517 Injection, anesthetic agent; superior hypogastric plexus
64520 Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic)
64530 Injection, anesthetic agent; celiac plexus, with or without radiologic monitoring
64620 Destruction by neurolytic agent, intercostal nerve

CLINICAL POLICY
POLICY TITLE Nerve Blocks and Neurolysis for Pain Management

CPT® Codes Description
64600 Destruction by neurolytic agent, trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch
64605 Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale
64624 Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed
64628 Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral
64640 Destruction by neurolytic agent; other peripheral nerve or branch
64680 Destruction by neurolytic agent, with or without radiologic monitoring; celiac plexus
64999 Unlisted procedure, nervous system
HCPCS Codes Description
N/A
Reviews, Revisions, and Approvals Revision Date Approval Date
Policy created and approved. 08/18 08/18
Centene Policy CP.MP. updated with OH Addendum 12/22 12/22
Policy moved to Ohio Specific template and Addendum language integrated into policy template as Policy Statement and Procedure. Annual Review with no material changes made to review criteria. 07/23 07/23
Annual Review. CPT Code 64628 added. Background added with no material change in review criteria. References reviewed and updated. External specialist reviewed. 07/24 09/24
Annual Review Added note in Description to refer to CP.MP.171 Facet Joint Interventions for facet joint injections and radiofrequency neurotomy and added note for Medicare plans to refer to MC.CP.MP.170 Peripheral Nerve Blocks and Ablation of Peripheral Nerves for Pain Management. Added clarifying verbiage regarding non-Medicare health plans in Policy/Criteria with no impact to criteria. Added clarifying language to Criteria IA.2. Updated Criteria IIA.1.c. to include application of lidocaine 10/25

  1. Aman MM, Mahmoud A, Deer T, et al. The American Society of Pain and Neuroscience (ASPN) Best Practices and Guidelines for the Interventional Management of Cancer-Associated Pain. J Pain Res. 2021;14:2139 to 2164. Published 2021 Jul 16. doi:10.2147/JPR.TS315585
  2. Filippiadis DK, Tselikas L, Tsitskari M, Kelekis A, de Baere T, Ryan AG. Percutaneous Neurolysis for Pain Management in Oncological Patients. Cardiovasc Intervent Radiol. 2019;42(6):791 to 799. doi:10.1007/s00270-019-02185-x
  3. Evidence Analysis Research Brief. Greater occipital nerve block for treatment of occipital neuralgia. Hayes. www.hayesinc.com. Published July 11, 2023. Accessed April 1, 2024.
Book a walkthrough

Walk through this policy with us

Review how this policy can be converted into cited criteria, prior authorization checks, and operational automation.